Official EU label nameGlossary entry 9987

ESCIN

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence

Markets checked

Markets with evidence

Evidence gaps

Resolved identifiers

Resolved substance identity

CAS:6805-41-0

EC:229-880-6

Ingredient index records:

ESCIN

Cosmetic functions: TONIC

Escin

Open full local profile

1 matched or reported name

ESCIN

Regulatory evidence across markets

None of the 13 markets tracked here holds an imported rule under the name ESCIN.

That is a statement about this inventory, not about the law: no imported rule is not evidence that a substance is permitted. A rule may exist under a different name, under a CAS or EC number this glossary entry does not carry, or in a dataset not yet imported.

Check the markets and their sources Search every market for this name

Chemical identity and properties

PubChem 2D chemical structure for CAS 6805-41-0

CAS 6805-41-0PubChem CID 6433489

Escin

Sodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and prognosis in massive cerebral infarction) and NCT05263167 (aimed at reducing edema after intracerebral hemorrhage). — DrugBank

IUPAC name: (2S,3S,4S,5R,6R)-6-[[(4S,6aR,6bS,8R,8aR,9R,10R,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(Z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxane-2-carboxylic acid;(2S,3S,4S,5R,6R)-6-[[(4S,6aR,6bS,8R,8aR,9R,10R,14bR)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(E)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxane-2-carboxylic acid

Molecular formula: C110H172O48
Molecular weight: 2262.5 g/mol
Exact mass: 2262.1051620 Da
Topological polar surface area: 776.0 Å²
Hydrogen-bond donors: 26
Hydrogen-bond acceptors: 48
Covalent units: 2
Defined stereocentres: 46

Also known as

Amorphous aescinRepariluEscinaRUU8G67GQMopinobiomoEskuzanFepalitanFeparil

12 more reported names

opino biomoopino-biomobeta AescinRefChem:921154229-880-6AescusanEscina [Italian]Reparilu [Czech]EINECS 229-880-6UNII-RUU8G67GQMA-4700YFESOSRPNPYODN-RSMWSHJLSA-N

Open full PubChem record PubChem annotations 3D structure image

External database identifiers

EPA DTXSID:DTXSID901021535

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

Each link searches that source for this identity. A link is a research route, not a claim that the source holds an exact record. What each source is, and its legal weight

Cosmetic Ingredient Review safety assessments FDA Global Substance Registration System ILO/WHO International Chemical Safety Cards Japan NITE-CHRIP NIOSH Pocket Guide to Chemical Hazards OECD eChemPortal US EPA CompTox CTX APIs

Take this record further

Screen in a formula Open standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision